mGluR5 Protein
Overview
mGluR5 (metabotropic glutamate receptor 5) is a G protein-coupled receptor (GPCR) encoded by the GRM5 gene in humans. As a member of the metabotropic glutamate receptor family, mGluR5 functions as a signal transduction protein that responds to the primary excitatory neurotransmitter glutamate. It belongs to Group I metabotropic glutamate receptors, alongside mGluR1, and is predominantly expressed in the central nervous system with particularly high concentrations in the striatum, hippocampus, cortex, and cerebellum. mGluR5 is located on neuronal cell bodies, dendrites, and postsynaptic terminals, where it mediates intracellular signaling cascades critical for synaptic plasticity, learning, and memory formation.
Function/Biology
mGluR5 operates as a transmembrane receptor that couples to phospholipase C (PLC) through activation of Gq/11 heterotrimeric G proteins. Upon glutamate binding to the receptor's extracellular N-terminal domain, mGluR5 undergoes conformational changes that activate intracellular signaling pathways. The activated PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), leading to IP3-mediated release of calcium from intracellular stores. This calcium mobilization activates downstream effectors including protein kinase C (PKC) and calcium-dependent phosphatases like calcineurin.
...mGluR5 Protein
Overview
mGluR5 (metabotropic glutamate receptor 5) is a G protein-coupled receptor (GPCR) encoded by the GRM5 gene in humans. As a member of the metabotropic glutamate receptor family, mGluR5 functions as a signal transduction protein that responds to the primary excitatory neurotransmitter glutamate. It belongs to Group I metabotropic glutamate receptors, alongside mGluR1, and is predominantly expressed in the central nervous system with particularly high concentrations in the striatum, hippocampus, cortex, and cerebellum. mGluR5 is located on neuronal cell bodies, dendrites, and postsynaptic terminals, where it mediates intracellular signaling cascades critical for synaptic plasticity, learning, and memory formation.
Function/Biology
mGluR5 operates as a transmembrane receptor that couples to phospholipase C (PLC) through activation of Gq/11 heterotrimeric G proteins. Upon glutamate binding to the receptor's extracellular N-terminal domain, mGluR5 undergoes conformational changes that activate intracellular signaling pathways. The activated PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), leading to IP3-mediated release of calcium from intracellular stores. This calcium mobilization activates downstream effectors including protein kinase C (PKC) and calcium-dependent phosphatases like calcineurin.
mGluR5 also couples to cAMP signaling through interactions with both stimulatory (Gs) and inhibitory (Gi/o) G proteins, depending on cellular context. The receptor exhibits functional heteromerization with mGluR1, allowing for coordinated modulation of glutamatergic signaling. Additionally, mGluR5 interacts with Homer proteins, scaffolding proteins that link the receptor to IP3 receptors and regulate calcium dynamics. The receptor undergoes agonist-dependent phosphorylation by G protein-coupled receptor kinases (GRKs) and subsequent β-arrestin binding, which terminates G protein signaling and initiates alternative signaling pathways.
Role in Neurodegeneration
mGluR5 dysfunction and dysregulation have been implicated in multiple neurodegenerative conditions. In Huntington's disease, excessive mGluR5 signaling contributes to excitotoxic neuronal death in striatal medium spiny neurons through heightened calcium mobilization and mitochondrial dysfunction. The mutant huntingtin protein alters Homer protein interactions with mGluR5, disrupting normal receptor coupling and calcium homeostasis. Conversely, mGluR5 hypofunction has been observed in Alzheimer's disease, where amyloid-beta pathology impairs receptor-mediated signaling and contributes to synaptic deterioration and cognitive decline.
In Parkinson's disease, altered mGluR5 expression in striatal circuits affects motor control through dysregulated glutamatergic signaling. Fragile X syndrome-associated neurodegeneration involves excessive mGluR5 signaling due to loss of fragile X mental retardation protein (FMRP), an inhibitory regulator of mGluR5-mediated translation. This leads to exaggerated IP3-dependent calcium signaling and dendritic spine abnormalities characteristic of the disease.
Molecular Mechanisms
The pathological contributions of mGluR5 in neurodegeneration involve multiple molecular mechanisms. Excessive mGluR5 activation increases intracellular calcium concentration, potentially triggering mitochondrial calcium overload, reactive oxygen species generation, and activation of pro-apoptotic cascades. Altered mGluR5 coupling to different G protein subtypes shifts the balance between excitatory and inhibitory signaling, disrupting normal synaptic plasticity mechanisms. In some contexts, mGluR5 overactivation impairs protein synthesis regulation through dysregulated extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin (mTOR) pathways.
Neuroinflammatory responses in neurodegeneration involve mGluR5 signaling on glial cells, particularly astrocytes and microglia. mGluR5 activation on these cells modulates release of pro-inflammatory cytokines and neurotrophic factors, influencing neuronal survival and degeneration rates.
Clinical/Research Significance
mGluR5 antagonists have emerged as therapeutic candidates for neurodegenerative diseases. Negative allosteric modulators (NAMs) of mGluR5 have demonstrated efficacy in preclinical models of Huntington's disease, fragile X syndrome, and Alzheimer's disease by reducing excessive receptor signaling. Clinical trials have evaluated mGluR5 inhibitors for these conditions, with particular promise in Huntington's disease where normalized mGluR5 signaling reduces striatal neurodegeneration.